Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Temozolomide and Atezolizumab as Second Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04919382
Recruitment Status : Recruiting
First Posted : June 9, 2021
Last Update Posted : February 10, 2022
Genentech, Inc.
Information provided by (Responsible Party):
Dwight Owen, Big Ten Cancer Research Consortium

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : December 31, 2023
Estimated Study Completion Date : December 31, 2024